PMID: 9558133Apr 29, 1998Paper

Population pharmacokinetic parameters of gentamicin in patients with solid tumors: estimation by one- and two-stage methods

Therapeutic Drug Monitoring
A OrtegaA Brugarolas

Abstract

Gentamicin monitoring has been improved with the introduction of Bayesian methods but the usefulness depends on the quality of the population parameters (PP) used. The objective of this study was to determine PP of gentamicin in patients with solid tumors. A total of 198 adult patients with cancer were included in the analysis. Population parameters were estimated by both a two-stage and a one-stage method (NPEM, Non Parametric Expectation Maximization). Individual parameters (IP) were estimated by the Sawchuk-Zaske method and by nonlinear regression. The estimated distribution volume and clearance of gentamicin (mean +/- SD) were 18.37 +/- 5.021 (0.30-0.32 l/kg of dosing weight) and 3.34 +/- 1.6 l/h, respectively. No significant differences between IP or PP obtained by the different methods were found. The results indicated a wide variability of gentamicin pharmacokinetics making monitoring necessary and that patients with solid tumors may have larger gentamicin volume and slower clearance than normal patients. These observations imply that different population pharmacokinetic parameters should be used for this group of patients.

References

Sep 1, 1979·Clinical Pharmacology and Therapeutics·L B SheinerV V Marathe
Oct 1, 1978·The Journal of Infectious Diseases·S N SchwartzA W Pasculle
Aug 1, 1976·Annals of Internal Medicine·J H Hull, F A Sarubbi
Apr 1, 1976·Journal of Pharmacokinetics and Biopharmaceutics·R J Sawchuk, D E Zaske
Jul 11, 1991·Antimicrobial Agents and Chemotherapy·J S BertinoB Rybicki
May 1, 1990·Antimicrobial Agents and Chemotherapy·R G ZeitanyM A Sigmon
May 1, 1988·The Medical Clinics of North America·S J Pancoast
Jun 1, 1986·Clinical Pharmacology and Therapeutics·T H GraselaR B Smith
Jun 1, 1983·Drug Intelligence & Clinical Pharmacy·G R MatzkeR L Lucarotti
Feb 1, 1994·Journal of Clinical Pharmacy and Therapeutics·J P OrdovásR López
May 1, 1993·Antimicrobial Agents and Chemotherapy·J F Inciardi, K K Batra

❮ Previous
Next ❯

Citations

Jul 10, 2008·Clinical Pharmacokinetics·Anthe S ZandvlietAlwin D R Huitema
May 22, 2002·Therapeutic Drug Monitoring·Matthijs de HoogAlexander A Vinks

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.